Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01%, Bimatoprost 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Artesia, California • El Paso, Texas

Conditions: Hypertension
Interventions: Aliskiren, Aliskiren plus placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metabolic Syndrome X, Insulin Resistance, Hypertension, Hypercholesterolemia, Obesity
Interventions: Exercise, Metformin; Behavioral · Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 20 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Glaucoma, Primary Open Angle
Interventions: ELIOS Procedure; Device
Lead sponsor: Elios Vision, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 20
States / cities: Glendale, Arizona • Petaluma, California • Fort Collins, Colorado + 16 more

Conditions: Hypertension, Elevated Blood Pressure
Interventions: Hot Yoga; Behavioral
Lead sponsor: Texas State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Marcos, Texas

Conditions: Hypertension in Pregnancy, Preeclampsia, Gestational Hypertension
Interventions: Social incentives-based program; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions: Inhaled Treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 91
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more

Conditions: Glaucoma
Interventions: Ripcord removal; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer
Interventions: Bevacizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Lifestyle Related Disease, Diabetes, Overweight and Obesity, Dyslipidemias, Hypertension, Cardiovascular Diseases
Interventions: Lifestyle Medicine; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Glaucoma
Interventions: POLAT-001, Latanoprost ophthalmic solution; Drug
Lead sponsor: Peregrine Ophthalmic; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Goose Creek, South Carolina

Conditions: Depression, Hypertension
Interventions: Collaborations in Health (COACH); Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 60 Years and older
Enrollment: 2,685 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 4
States / cities: New Orleans, Louisiana • Ann Arbor, Michigan • Rochester, New York + 1 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Beraprost Sodium Modified Release; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Torrance, California • Naperville, Illinois • New York, New York + 3 more

Conditions: Pulmonary Arterial Hypertension
Interventions: UT-15C SR, Tyvaso Inhalation Solution; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Birmingham, Alabama • Rochester, Minnesota • St Louis, Missouri + 3 more

Conditions: Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Interventions: Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin; Drug · Radiation
Lead sponsor: Paul Szabolcs; Other
Eligibility: 8 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: High Blood Pressure
Interventions: Acupuncture; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Norman, Oklahoma

Conditions: Essential Hypertension
Interventions: Motivational Interviewing; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Primary Open Angle, Ocular Hypertension
Interventions: WB007 0.05%, WB007 0.15%, WB007 0.4%, Timolol 0.5%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hypertension, Type 2 Diabetes Mellitus
Interventions: Carvedilol, Metoprolol; Drug
Lead sponsor: St. Paul Heart Clinic; Other
Eligibility: 30 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Glaucoma
Interventions: Latanoprost, Bimatoprost, Travoprost, Timolol, Dorzolamide, Brinzolamide, Acetazolamide, Methazolamide; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Systemic Sclerosis, Scleroderma, Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 25
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 18 more

Conditions: Microvascular Dysfunction
Interventions: Low sodium no cheese, Low sodium cheese, High sodium no cheese, High sodium cheese; Dietary Supplement
Lead sponsor: Lacy Alexander; Other
Eligibility: 55 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Hypertension
Interventions: Patient educational letter to engage provider in hypertension rx discussion, Financial incentive (Arms B and C) and health educator phone call (Arm C); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 834 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Iowa City, Iowa • Minneapolis, Minnesota

Conditions: Hypertension, Pulmonary
Interventions: Telephone concept elicitation interview; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet

Physical Inactivity and Insulin Resistance in Skeletal Muscle.

Excimer Laser Trabeculostomy Glaucoma Treatment Study

The Effects of Hot Yoga on Vascular Function

Randomized Clinical Trial to Increase Physical Activity After a a Hypertensive Pregnancy

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

The Effect of Scheduled Ripcord Removal on the Outcomes of Baerveldt 350 Implants

Hypertension in Breast Cancer Patients Receiving Bevacizumab

Evaluation of a Lifestyle Medicine Practice

POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma

Chinese Older Adults-Collaboration in Health (COACH)Study

Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Acupuncture Treatment on Cerebral Blood Flow

Motivational Interviewing

Safety and IOP-Lowering Effects of WB007

Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes

Stop Retinal Ganglion Cell Dysfunction Study

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Cheese Consumption and Human Microvascular Function

Implementing Evidence Based Treatment of Hypertension

Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects